CLDX Stock Celldex Therapeutics, Inc.
US · NasdaqCMLast in our picks 2026-10-24 — not in the current list; analysis below is from that screen
Promising immunology pipeline creates substantial catalyst-driven upside for risk-tolerant investors.
Future value: $63.07 (+115.63%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Strong-buy consensus and repeated analyst support highlight pipeline potential.
- ▾Below 50-day MA (-16.94%)
- ▸~116% upside to price target
Is CLDX a buy right now?
Trend: CLDX is trading below the 50-day average (-16.33%), RSI 61 — neutral momentum, with a 3-month return of -17.79%.
Valuation & quality: Celldex Therapeutics, Inc. trades on forward P/E -6.9, price-to-book 3.21; fundamentals show net margin 0.0%, return on equity -43.9%, revenue growth -97.0% year on year.
Analyst consensus: 14 analysts have a mean 12-month price target of $63.07 (+115.6% vs the last close; range $28.00 – $100.00), consensus rating “strong buy”.
Our screen: BUY (score 2) — Promising immunology pipeline creates substantial catalyst-driven upside for risk-tolerant investors.
Computed from end-of-day data; not personal advice.
Our track record with CLDX
First flagged in our daily picks as BUY on 2026-10-22 at $29.37 — -0.4% since. It has appeared in the picks on 3 days.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +5.40% | +3.70% | -4.40% | +18.40% | +2.30% | +4.10% | -18.20% | -9.80% |
Fundamentals
Analyst price target
Technical signals
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Sector: Healthcare · Industry: Biotechnology · United States · 198 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.